Therapies aimed to target TGFβ signaling have improved NKG2D-mediated tumor recognition and enhanced tumor cell lysis by NK cells and T cells (Y. S. Lee et al., 2021; Otegbeye et al., 2018; Tran et al., 2017). The gene discussed is KLRK1; the disease is neoplasm.